6:10 PM
 | 
Apr 09, 2009
 |  BC Extra  |  Company News

Celldex licenses FLT3, CD40 ligands from Amgen

Amgen Inc. (NASDAQ:AMGN) granted Celldex Therapeutics Inc. (NASDAQ:CLDX) exclusive, worldwide rights to develop and commercialize FMS-related tyrosine kinase 3 (...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >